	US 12,329,786 B2
	Regulate gut microbiota to treat neurodegenerative disorders
Sarkis K. Mazmanian, Porter Ranch, CA (US); and Timothy R. Sampson, Los Angeles, CA (US)
Assigned to CALIFORNIA INSITUTE OF TECHNOLOGY, Pasadena, CA (US)
Filed by California Institute of Technology, Pasadena, CA (US)
Filed on Jun. 15, 2023, as Appl. No. 18/335,889.
Application 18/335,889 is a continuation of application No. 16/302,321, granted, now 11,707,493, previously published as PCT/US2017/033881, filed on May 22, 2017.
Claims priority of provisional application 62/443,952, filed on Jan. 9, 2017.
Claims priority of provisional application 62/370,578, filed on Aug. 3, 2016.
Claims priority of provisional application 62/340,408, filed on May 23, 2016.
Prior Publication US 2024/0000862 A1, Jan. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/741 (2015.01); A61K 38/14 (2006.01); C12Q 1/6883 (2018.01); C12Q 1/689 (2018.01); G01N 33/569 (2006.01)

CPC A61K 35/741 (2013.01) [A61K 38/14 (2013.01); C12Q 1/6883 (2013.01); C12Q 1/689 (2013.01); G01N 33/56911 (2013.01); G01N 2800/2835 (2013.01)]

14 Claims

1. A method of reducing neuroinflammation in a subject having a disease, the method comprising:

administering a composition comprising an inhibitor of a short chain fatty acid (SCFA) comprising propionate or butyrate; and

increasing a level of a Parkinson's disease (PD)-protective bacteria in a gut microbiota of the subject; or

decreasing a level of a PD-enhancing bacteria in a gut microbiota of the subject,

wherein increasing the level of the PD-protective bacteria or decreasing the level of the PD-enhancing bacteria reduces neuroinflammation in the subject,

wherein the PD-protective bacteria is Lachnospiraceae, Rikenellaceae, Peptostreptococcaceae, or Butyricicoccus and

wherein the PD-enhancing bacteria belongs to Proteus species, Bilophila species, Roseburia species, Pseudoramibacter Eubacterium, or Veillonellaceae family.